ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS

Blood Cancer J. 2017 Nov 27;7(12):633. doi: 10.1038/s41408-017-0004-0.

¹ Malignant Hematology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 36612, USA. david.sallman@moffitt.org.
² Malignant Hematology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 36612, USA.
³ Cote D'azur University, Nice Sophia Antipolis University, Hematology Department, CHU Nice, Nice, 06200, France.
⁴ INSERM U1065, Mediterranean center of molecular medicine, Nice, 06200, France.
⁵ Navigate BioPharma Services, Inc., a Novartis company, Carlsbad, CA, 92008, USA.
⁶ Hematopathology and Laboratory Medicine Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 36612, USA.

No abstract available

Publication types